Novavax’s Big FDA Win Sends Stock Soaring

Novavax just got the green light from the FDA for its new protein-based COVID-19 shot, Nuvaxovid, and their stock shot up 25%! This vaccine is aimed at older adults and people with health conditions, and it’s different from the usual mRNA shots. Plus, Sanofi is teaming up with them and dropping $175 million on the deal, with more royalties on the way. Looks like Novavax is back in the game! #Novavax #COVID19 #VaccineNews #StockMarket #FDAApproval #Health